What is HC Wainwright's Estimate for KYMR FY2025 Earnings?

Key Points

• HC Wainwright has cut its FY2025 earnings per share estimate for Kymera Therapeutics from ($3.09) to ($3.26), while maintaining a "Buy" rating and a target price of $60.
• Kymera Therapeutics shares recently rose by 2.2%, trading at $42.48, with a market capitalization of $3.04 billion.
• Multiple analysts have provided differing price targets for Kymera, with the range from $51.00 to $72.00, indicating a generally positive outlook from the research community.

Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) - Analysts at HC Wainwright decreased their FY2025 earnings estimates for shares of Kymera Therapeutics in a research note issued to investors on Tuesday, August 12th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings of ($3.26) per share for the year, down from their prior estimate of ($3.09). HC Wainwright currently has a "Buy" rating and a $60.00 price target on the stock. The consensus estimate for Kymera Therapeutics' current full-year earnings is ($2.79) per share. HC Wainwright also issued estimates for Kymera Therapeutics' FY2026 earnings at ($3.37) EPS, FY2027 earnings at ($3.66) EPS, FY2028 earnings at ($3.71) EPS and FY2029 earnings at ($3.36) EPS.

KYMR has been the topic of several other research reports. Jefferies Financial Group set a $64.00 price target on shares of Kymera Therapeutics and gave the stock a "buy" rating in a research note on Wednesday, June 25th. Stifel Nicolaus started coverage on shares of Kymera Therapeutics in a research report on Tuesday, May 20th. They set a "buy" rating and a $55.00 target price on the stock. Oppenheimer reaffirmed an "outperform" rating and set a $53.00 price target (down previously from $56.00) on shares of Kymera Therapeutics in a research note on Friday, June 27th. Bank of America raised Kymera Therapeutics from a "neutral" rating to a "buy" rating and set a $51.00 price objective on the stock in a research note on Monday, June 2nd. Finally, The Goldman Sachs Group raised Kymera Therapeutics to a "strong-buy" rating in a research report on Tuesday, July 15th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, sixteen have issued a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat, Kymera Therapeutics currently has a consensus rating of "Buy" and an average target price of $59.11.

Kymera Therapeutics Price Performance

Shares of NASDAQ:KYMR traded up $0.99 on Friday, hitting $43.62. 665,521 shares of the company's stock were exchanged, compared to its average volume of 641,325. The stock has a market capitalization of $3.12 billion, a price-to-earnings ratio of -12.57 and a beta of 2.18. Kymera Therapeutics has a 12 month low of $19.44 and a 12 month high of $53.27. The business's 50 day simple moving average is $44.57 and its two-hundred day simple moving average is $36.47.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last announced its quarterly earnings data on Monday, August 11th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.83) by ($0.12). Kymera Therapeutics had a negative return on equity of 31.60% and a negative net margin of 616.03%. The firm had revenue of $11.48 million during the quarter, compared to the consensus estimate of $17.37 million. The firm's revenue for the quarter was down 55.1% on a year-over-year basis. During the same period in the previous year, the business earned ($0.58) EPS.

Insider Activity

In other news, Director Bvf Partners L. P/Il bought 317,167 shares of the stock in a transaction on Monday, June 30th. The stock was bought at an average cost of $44.00 per share, for a total transaction of $13,955,348.00. Following the completion of the purchase, the director directly owned 2,798,795 shares in the company, valued at approximately $123,146,980. The trade was a 12.78% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Elena Ridloff sold 12,000 shares of Kymera Therapeutics stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $46.10, for a total transaction of $553,200.00. The disclosure for this sale can be found here. Insiders have sold a total of 48,349 shares of company stock worth $2,334,301 over the last 90 days. 16.01% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Hudson Bay Capital Management LP acquired a new stake in Kymera Therapeutics in the second quarter worth about $218,000. Tower Research Capital LLC TRC raised its position in shares of Kymera Therapeutics by 111.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,425 shares of the company's stock valued at $237,000 after purchasing an additional 2,858 shares during the last quarter. Vident Advisory LLC acquired a new stake in Kymera Therapeutics in the 2nd quarter worth approximately $376,000. Oxford Asset Management LLP purchased a new stake in Kymera Therapeutics during the 2nd quarter worth approximately $201,000. Finally, Octagon Capital Advisors LP purchased a new stake in Kymera Therapeutics during the 2nd quarter worth approximately $11,608,000.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.